Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-MASCT in Advanced NSCLC
NCT03205930Phase 2Unknown
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Aug 2017
- Primary completion
- Oct 2019
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Neo-MASCT in non-small cell lung cancer (NSCLC), sponsored by First People's Hospital of Lianyungang City. Primary endpoint: Number of participants with treatment-related adverse events. Status: unknown.
02
Drugs
Neo-MASCT
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03205930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205930.